This clinical trial is focused on studying a type of skin cancer called cutaneous squamous cell carcinoma (cSCC), which is a form of cancer that can be surgically removed. The study is testing a new treatment approach using a combination of two medications: V940 (also known as mRNA-4157) and pembrolizumab (also known as KEYTRUDA). V940 is a special type of treatment that uses a synthetic messenger RNA (mRNA) to help the body recognize and fight cancer cells. Pembrolizumab is a medication that helps the immune system attack cancer cells more effectively.

The purpose of this study is to compare the effectiveness of the combination of V940 and pembrolizumab with the standard treatment options available for cSCC. Participants in the study will receive either the combination of V940 and pembrolizumab, pembrolizumab alone, or the standard treatment. The study will follow participants over a period of time to observe how well the treatments work in preventing the cancer from returning or spreading. Participants will receive the treatments through injections or infusions, and their health will be monitored regularly by the study team.

This study aims to provide valuable information on whether the new combination treatment can improve outcomes for people with resectable locally advanced cSCC. By participating in this study, researchers hope to find better ways to treat this type of skin cancer and improve the quality of life for those affected by it.